Tomasz Byrski

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations

Pharmacy, Oncology, Pharmacotherapy +14

Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies

Xiaohong R. Yang, Jenny Chang‐Claude, Ellen L. Goode et al. · JNCI Journal of the National Cancer Institute · 2010 · 716 citations · Full text

Medicine, Cancer Biology, Oncology +16

CHEK2 Is a Multiorgan Cancer Susceptibility Gene

Cezary Cybulski, Bohdan Górski, Tomasz Huzarski et al. · The American Journal of Human Genetics · 2004 · 555 citations · Full text

Medicine, Molecular Genetics, Oncology +9

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

Stig E. Bojesen, Karen A. Pooley, Sharon E. Johnatty et al. · Nature Genetics · 2013 · 540 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14

Association of Type and Location of<i>BRCA1</i>and<i>BRCA2</i>Mutations With Risk of Breast and Ovarian Cancer

Timothy R. Rebbeck, Nandita Mitra, Fei Wan et al. · JAMA · 2015 · 509 citations · Full text

Medicine, Genetics, Oncology +17